- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02076100
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
December 3, 2018 updated by: Merck Sharp & Dohme LLC
A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection
This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection.
Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tolerated dose of Ruzasvir.
Part I will be for participants with hepatitis C virus (HCV) genotype 3 (GT3) and will run first: Part II will be for participants with HCV genotype 1a (GT1a), and Part III will be for participants with HCV genotype 2b (GT2b).
Parts II and III may run concurrently.
The primary study hypothesis is that a safe and tolerable dose of Ruzasvir that reduces viral load will be found to support further clinical investigation.
Study Overview
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body mass index (BMI) >=18 to<=37 kg/m^2
- In general good health, except for HCV infection
- Clinical diagnosis of chronic HCV infection exclusively GT3 (Panels A-D) or exclusively GT1a (Panels E-F), or exclusively GT2b (Panels G-H).
- Must agree to follow the smoking restrictions defined by the CRU
- Must agree to use an acceptable method of contraception during the study and for 90 days after the last dose of ruzasvir
Exclusion Criteria:
- Clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormalities or diseases
- History of clinically significant hepatic disease, Gilbert's disease or biliary tract disease
- History of cancer (malignancy) with the exception of adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, or successfully-treated malignancies ≥10 years prior to screening
- History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food
- Positive for hepatitis B or human immunodeficiency virus (HIV)
- Major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to screening
- Participated in another investigational trial within 4 weeks prior to the screening visit
- QTc interval >=470 msec (for males) or >= 480 msec (for females)
- Unable to refrain from or anticipates use of any medication (prescription and/or non-prescription) or herbal remedies beginning approximately 2 weeks prior to first study drug dose, throughout the trial until the post-trial visit
- Consumes >2 glasses of alcoholic beverages per day
- Regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 12 months
- Evidence or history of chronic hepatitis not caused by HCV
- Previous treatment with other HCV NS5A inhibitors such as MK-8742, daclatasvir, or MK-8325
- Treatment with other HCV therapies such as the HCV protease
- Evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (Metavir score >=3)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part I GT3 Participants
Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
|
Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Other Names:
|
Experimental: Part II GT1a Participants
Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
|
Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Other Names:
|
Experimental: Part III GT2b Participants
Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
|
Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline
Time Frame: Baseline and up to Day 5
|
Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels.
Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment.
The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10.
A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.
|
Baseline and up to Day 5
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
Time Frame: Up to 61 days
|
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
|
Up to 61 days
|
Number of Participants Who Discontinued Study Drug Due To An AE
Time Frame: Up to 5 days
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
|
Up to 5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2014
Primary Completion (Actual)
November 15, 2015
Study Completion (Actual)
November 15, 2015
Study Registration Dates
First Submitted
February 27, 2014
First Submitted That Met QC Criteria
February 27, 2014
First Posted (Estimate)
March 3, 2014
Study Record Updates
Last Update Posted (Actual)
December 24, 2018
Last Update Submitted That Met QC Criteria
December 3, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Infections
- Communicable Diseases
- Hepatitis
- Hepatitis A
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Ruzasvir
Other Study ID Numbers
- 8408-003
- 2013-005094-41 (EudraCT Number)
- MK-8408-003 (Other Identifier: Merck Protocol Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Infection
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Gilead SciencesCompleted
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityRecruitingChronic Hepatitis C InfectionChina
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on Ruzasvir
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.RecruitingHealthy Volunteer StudyUnited States
-
Merck Sharp & Dohme LLCTerminated
-
Atea Pharmaceuticals, Inc.Not yet recruiting
-
Atea Pharmaceuticals, Inc.RecruitingHepatitis C | Hepatitis C, Chronic | HCV | Chronic Hepatitis C Virus | Hepatic CirrhosisTurkey, Brazil, Romania, Canada, Philippines, Pakistan, South Africa, Moldova, Republic of, India, Korea, Republic of, Mauritius
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCTerminated